Cocrystal Pharma, Inc.

Develops novel antiviral drugs for influenza, coronaviruses, norovirus, and hepatitis C.

COCP | US

Overview

Corporate Details

ISIN(s):: US19188J4094
LEI:
Country:: United States of America
Address:: 19805 N. CREEK PARKWAY, 98011 BOTHELL
Website:: https://www.cocrystalpharma.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that discovers and develops novel antiviral therapeutics for serious and chronic viral diseases. The company utilizes its proprietary structure-based drug design technologies and Nobel Prize-winning expertise to create antiviral drugs that target the viral replication process. Its development pipeline includes candidates for the treatment of influenza, coronaviruses (including SARS-CoV-2), norovirus, and hepatitis C. Key programs in its portfolio are at various stages of clinical development, including a Phase 2 trial for an influenza A inhibitor (CC-42344) and a Phase 1 trial for a pan-viral protease inhibitor (CDI-988) targeting norovirus and coronaviruses.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cocrystal Pharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cocrystal Pharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Cocrystal Pharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
MetaVia Inc. A clinical-stage biotech developing novel drugs for cardiometabolic diseases like obesity and MASH.	United States of America	MTVA
Metsera, Inc. Develops potent, long-acting oral & injectable therapies for obesity & metabolic diseases.	United States of America	MTSR
Mezzion Pharma Co., Ltd. Develops and out-licenses novel therapeutics like udenafil, with a focus on rare diseases.	South Korea	140410
MFC Co., Ltd. A GMP-certified CDMO/CMO developing and manufacturing APIs for the global pharma sector.	South Korea	432980
Milestone Pharmaceuticals Inc. Developing a self-administered nasal spray for at-home treatment of acute cardiac events.	United States of America	MIST
MIMEDX GROUP, INC. Provides placental-based biologics for advanced wound care, surgical, and burn applications.	United States of America	MDXG
Mind Medicine (MindMed) Inc. Developing psychedelic-inspired medicines and novel therapies for brain health disorders.	United States of America	MNMD
Mineralys Therapeutics, Inc. Developing targeted treatments for hypertension & CKD driven by elevated aldosterone.	United States of America	MLYS
MiNK Therapeutics, Inc. Developing allogeneic iNKT cell therapies for cancer and immune-mediated diseases.	United States of America	INKT
MIRA PHARMACEUTICALS, INC. Develops novel ketamine and THC analogs for neurologic and neuropsychiatric disorders.	United States of America	MIRA